Protherics PLC
Issue of Shares
London, UK; Brentwood, TN, US: 4 July 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, announces that
the Company has today issued 1,741,911 ordinary shares pursuant to the
MacroMed Acquisition Agreement ("Agreement") approved by
shareholders at the Company's Extraordinary General Meeting held on 3
January 2007 and details of which were contained in the Company's
announcement dated 7 December 2006.
Under the terms of the Agreement 10% of the ordinary shares issuable
upon the acquisition of MacroMed Inc. were held back for a period of 18
months from the date of the Acquisition and have become issuable on the
basis that no claims against the MacroMed vendors have arisen over that
period.
Accordingly, application has today been made to the UK Listing
Authority of the London Stock Exchange for the listing of 1,741,911
ordinary shares of 2p each in the Company. The Shares will rank
equally with the existing issued ordinary shares of the Company and are
expected to be admitted to the Official List and commence trading on
or around 9 July 2008.
Following admission of these ordinary shares, the Company's
issued share capital will be 342,159,034 ordinary shares.
/ Ends /
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518000
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com